ATE114474T1 - Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes. - Google Patents

Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes.

Info

Publication number: ATE114474T1
Authority: AT; Austria
Prior art keywords: blood glucose; aica; lowering blood; ribosiden; administration
Prior art date: 1989-01-24

Application number

AT90903063T

Other languages

English (en)

Inventor

Harry E Gruber

Ronald E Tuttle

Clinton E Browne

Bheemarao G Ugarkar

Jack W Reich

Ernest Kurt Metzner

Paul J Marangos

Original Assignee

Gensia Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-01-24

Filing date

1990-01-24

Publication date

1994-12-15

1989-01-24 Priority claimed from US07/301,222 external-priority patent/US5082829A/en

1989-01-24 Priority claimed from US07/301,453 external-priority patent/US5200525A/en

1990-01-24 Application filed by Gensia Pharma filed Critical Gensia Pharma

1994-12-15 Application granted granted Critical

1994-12-15 Publication of ATE114474T1 publication Critical patent/ATE114474T1/de

Links

WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract 3
239000008280 blood Substances 0.000 title abstract 3
210000004369 blood Anatomy 0.000 title abstract 3
239000008103 glucose Substances 0.000 title abstract 3
DVNYTAVYBRSTGK-UHFFFAOYSA-N 5-aminoimidazole-4-carboxamide Chemical compound NC(=O)C=1N=CNC=1N DVNYTAVYBRSTGK-UHFFFAOYSA-N 0.000 title 1
210000005097 arteria cerebelosa anteroinferior Anatomy 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
RTRQQBHATOEIAF-UHFFFAOYSA-N AICA riboside Natural products NC1=C(C(=O)N)N=CN1C1C(O)C(O)C(CO)O1 RTRQQBHATOEIAF-UHFFFAOYSA-N 0.000 abstract 4
RTRQQBHATOEIAF-UUOKFMHZSA-N acadesine Chemical compound NC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RTRQQBHATOEIAF-UUOKFMHZSA-N 0.000 abstract 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
229940002612 prodrug Drugs 0.000 abstract 2
239000000651 prodrug Substances 0.000 abstract 2
OOXNYFKPOPJIOT-UHFFFAOYSA-N 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine;dihydrochloride Chemical compound Cl.Cl.C=12C(N)=NC=NC2=NC(C=2C=NC(=CC=2)N2CCOCC2)=CC=1C1=CC=CC(Br)=C1 OOXNYFKPOPJIOT-UHFFFAOYSA-N 0.000 abstract 1
108010076278 Adenosine kinase Proteins 0.000 abstract 1
102100032534 Adenosine kinase Human genes 0.000 abstract 1
208000013016 Hypoglycemia Diseases 0.000 abstract 1
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
206010022489 Insulin Resistance Diseases 0.000 abstract 1
230000007812 deficiency Effects 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
230000002218 hypoglycaemic effect Effects 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
230000001575 pathological effect Effects 0.000 abstract 1
208000011580 syndromic disease Diseases 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/052—Imidazole radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Hematology (AREA)
Obesity (AREA)
Genetics & Genomics (AREA)
Emergency Medicine (AREA)
Biotechnology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
External Artificial Organs (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Prostheses (AREA)

AT90903063T 1989-01-24 1990-01-24 Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes. ATE114474T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US07/301,222 US5082829A (en)	1989-01-24	1989-01-24	AICA riboside prodrugs
US07/301,453 US5200525A (en)	1989-01-24	1989-01-24	Anti-seizure compounds
US40810789A	1989-09-15	1989-09-15

Publications (1)

Publication Number	Publication Date
ATE114474T1 true ATE114474T1 (de)	1994-12-15

Family

ID=27404800

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT90903063T ATE114474T1 (de)	1989-01-24	1990-01-24	Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes.

Country Status (13)

Country	Link
EP (1)	EP0427799B1 (de)
JP (1)	JPH03504728A (de)
KR (1)	KR910700057A (de)
AT (1)	ATE114474T1 (de)
AU (2)	AU5086190A (de)
CA (1)	CA2008325A1 (de)
DE (1)	DE69014562T2 (de)
DK (1)	DK0427799T3 (de)
FI (1)	FI904694A0 (de)
IE (1)	IE75372B1 (de)
IL (1)	IL93164A0 (de)
NO (1)	NO904149L (de)
WO (1)	WO1990009163A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5214048A (en) *	1987-05-19	1993-05-25	Nippon Kayaku Kabushiki Kaisha	Oxetanocins
US5736531A (en) *	1987-10-28	1998-04-07	Pro-Neuron, Inc.	Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US7776838B1 (en)	1987-10-28	2010-08-17	Wellstat Therapeutics Corporation	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US5968914A (en) *	1987-10-28	1999-10-19	Pro-Neuron, Inc.	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US5202459A (en) *	1989-11-07	1993-04-13	Nippon Kayaku Kabushiki Kaisha	Process for producing cyclobutane derivative
JPH0615556B2 (ja) *	1989-11-10	1994-03-02	旭化成工業株式会社	４―カルバモイル―１―β―Ｄ―リボフラノシル―イミダゾリウム―５―オレイト無水結晶
US5324730A (en) *	1990-05-24	1994-06-28	Nippon Kayaku Kabushiki Kaisha	Phenoxyphosphoryloxymethyl cyclobutyl purines
IL99124A (en) *	1990-08-10	1998-02-22	Gensia Pharma	Substituted imidazole analogs of aica riboside
US5236908A (en) *	1991-06-07	1993-08-17	Gensia Pharmaceuticals, Inc.	Methods of treating injury to the central nervous system
IL103294A0 (en) *	1991-09-30	1993-05-13	Gensia Pharma	Pharmaceutical compositions for preventing tissue damage associated with decreased blood flow
IL108523A0 (en) *	1993-02-03	1994-05-30	Gensia Inc	Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
RU2153873C2 (ru) *	1994-08-09	2000-08-10	Кортендо АБ	Применение кетоконазола и родственных веществ в лекарствах, предназначенных для лечения диабета типа ii
DE69819311T2 (de)	1997-03-07	2004-07-29	Metabasis Therapeutics Inc., San Diego	Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
US6054587A (en)	1997-03-07	2000-04-25	Metabasis Therapeutics, Inc.	Indole and azaindole inhibitors of fructose-1,6-bisphosphatase
EP1402895A1 (de) *	1997-03-07	2004-03-31	Metabasis Therapeutics, Inc.	Benzimidazolinhibitoren der Fructose 1,6-biphosphatase
US6284748B1 (en)	1997-03-07	2001-09-04	Metabasis Therapeutics, Inc.	Purine inhibitors of fructose 1,6-bisphosphatase
US6312662B1 (en)	1998-03-06	2001-11-06	Metabasis Therapeutics, Inc.	Prodrugs phosphorus-containing compounds
AU2003242500B2 (en) *	1998-09-09	2006-11-02	Metabasis Therapeutics, Inc.	Novel Heteroaromatic Inhibitors of Fructose 1,6-bisphosphatase
CN100349904C (zh) *	1998-09-09	2007-11-21	症变治疗公司	新的果糖1,6－二磷酸酶的杂芳族抑制剂
KR100818845B1 (ko)	1998-09-09	2008-04-01	메타베이시스 테라퓨틱스, 인크.	신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제
US6756360B1 (en)	1998-12-24	2004-06-29	Metabasis Therapeutics, Inc.	Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
PL352756A1 (en) *	1998-12-24	2003-09-08	Metabasis Therapeutics, Inc.	A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
JP2003525944A (ja)	2000-03-08	2003-09-02	メタバシス・セラピューティクス・インコーポレイテッド	新規アリールフルクトース−１，６−ビスホスファターゼ阻害剤
US7563774B2 (en)	2000-06-29	2009-07-21	Metabasis Therapeutics, Inc.	Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
EP1372660A2 (de) *	2000-07-06	2004-01-02	Metabasis Therapeutics, Inc.	Fbpase inhibitoren in kombination mit antidiabetika für die behandlung von diabetes
ES2192495B1 (es)	2002-03-21	2005-02-16	Universidad De Barcelona	Nuevo uso terapeutico del ribosido de 5-aminoimidazol-4-carboxamida (acadesina).
EP1752450A1 (de)	2005-08-01	2007-02-14	Merck Sante	Imidazolderivate als Fruktose-1,6-biphosphataseinhibitoren und pharmazeutische Zusammensetzungen diese enthaltend
WO2008086341A1 (en) *	2007-01-09	2008-07-17	Pericor Therapeutics, Inc.	Methods. compositions, and formulations for preventing or reducing adverse effects in a patient
EP2058308A1 (de)	2007-11-12	2009-05-13	Merck Sante	Benzimidazoldihydrothiadiazinonderivate als Fructose-1,6-biphosphatase-Hemmer und diese enthaltende pharmazeutische Zusammensetzungen.
JP5591245B2 (ja) *	2008-10-03	2014-09-17	ペリコーセラピューティクス，インコーポレイテッド	急性心不全の治療のための方法および組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1535561A (fr) *	1966-06-18	1968-08-09	Ajinomoto Kk	Méthode de préparation de l'adénine, de ses dérivés et intermédiaires
US4575498A (en) *	1983-07-21	1986-03-11	Duke University	Method for restoring depleted purine nucleotide pools
AU5668886A (en) *	1986-03-27	1987-10-20	Harry Edward Gruber	A method of increasing adenosine excretion
US4912092A (en) *	1986-03-27	1990-03-27	The Regents Of The University Of California	Methods for increasing extracellular adenosine and for stabilizing mast cells

1990
- 1990-01-24 DE DE69014562T patent/DE69014562T2/de not_active Expired - Fee Related
- 1990-01-24 IL IL93164A patent/IL93164A0/xx unknown
- 1990-01-24 FI FI904694A patent/FI904694A0/fi not_active Application Discontinuation
- 1990-01-24 DK DK90903063.7T patent/DK0427799T3/da active
- 1990-01-24 CA CA002008325A patent/CA2008325A1/en not_active Abandoned
- 1990-01-24 AU AU50861/90A patent/AU5086190A/en not_active Abandoned
- 1990-01-24 AT AT90903063T patent/ATE114474T1/de active
- 1990-01-24 JP JP2503252A patent/JPH03504728A/ja active Pending
- 1990-01-24 IE IE27490A patent/IE75372B1/en not_active IP Right Cessation
- 1990-01-24 EP EP90903063A patent/EP0427799B1/de not_active Expired - Lifetime
- 1990-01-24 WO PCT/US1990/000359 patent/WO1990009163A2/en not_active Ceased
- 1990-09-24 NO NO90904149A patent/NO904149L/no unknown
- 1990-09-26 KR KR1019900702149A patent/KR910700057A/ko not_active Withdrawn
1993
- 1993-12-13 AU AU52360/93A patent/AU5236093A/en not_active Abandoned

Also Published As

Publication number	Publication date
IL93164A0 (en)	1990-11-05
EP0427799A4 (en)	1991-07-24
KR910700057A (ko)	1991-03-13
DK0427799T3 (da)	1995-05-08
WO1990009163A3 (en)	1991-01-24
AU5086190A (en)	1990-09-05
IE75372B1 (en)	1997-09-10
CA2008325A1 (en)	1990-07-24
FI904694A7 (fi)	1990-09-24
JPH03504728A (ja)	1991-10-17
EP0427799B1 (de)	1994-11-30
NO904149L (no)	1990-11-26
FI904694A0 (fi)	1990-09-24
DE69014562D1 (de)	1995-01-12
AU5236093A (en)	1994-02-24
DE69014562T2 (de)	1995-06-22
EP0427799A1 (de)	1991-05-22
IE900274L (en)	1990-07-24
WO1990009163A2 (en)	1990-08-23
NO904149D0 (no)	1990-09-24

Publication	Publication Date	Title
ATE114474T1 (de)	1994-12-15	Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes.
PL346520A1 (en)	2002-02-11	Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
DE60125734D1 (en)	2007-02-15	Neue aryl fructose-1,6-bisphosphatase inhibitoren
HU907065D0 (en)	1991-05-28	Process for manufacturing pharmaceutical preparative of transdermal action containing 2-amino-6-(n-propyl-amino)-4,5,6,7-tetrahydro-benzothiazole
EP0464638A3 (en)	1992-09-02	Oligonucleotide analogues with terminal 3'-3' or 5'-5'-internucleotide linkages
ES2075468T3 (es)	1995-10-01	Vehiculos de suministro de farmacos suspendidos en un portador perfluorado no acuoso.
DE10199020I2 (de)	2004-05-06	Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
EP0330047A3 (en)	1990-12-19	Method for the sterilization of blood, blood derivatives, plasma derivatives, cell suspensions or the like
NO882853L (no)	1989-01-18	Korreksjon med dobbeltraadet rna av unormale tilstander i immunkomplekser som er i omloep, og i monocyttfunkjon.
NL960024I1 (nl)	1996-12-02	Farmaceutisch preparaat omvattend 3'-deoxythymidine-2'-een (3'-deoxy-2',3'-didehydrothymidine) voor de behandeling van met retrovirus gesmette patiënten.
EP0354322A3 (de)	1990-06-13	Antidiabetische alpha-substituierte Phosphonate
ES2138729T3 (es)	2000-01-16	Metodos de diagnostico de la preeclampsia.
IE882593L (en)	1989-02-26	Aristeromycin/adenosine derivatives
ES2080736T3 (es)	1996-02-16	Uso de 2,3,4,5-tetrahidro-1h-3-benzazepinas en el tratamiento de trastornos neurologicos.
ATE107509T1 (de)	1994-07-15	Nusammensetzung mit udpg und anderen antitumormitteln zur behandlung von tumoren.
ATE207357T1 (de)	2001-11-15	Verwendung von cotinin zur linderung des tabakentzugssyndrom
ATE501760T1 (de)	2011-04-15	E5564 zur verwendung in der behandlung von allograft-abstossung oder host-versus-graft- erkrankungen
SE8802323D0 (sv)	1988-06-21	8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it
Senczuk et al.	1984	Toxicodynamic propertes of toluidines. Part II. Blood absorption of toluidines.
GB9818650D0 (en)	1998-10-21	Therapeutic compounds and methods of making and using the same
UA10335A (uk)	1996-12-25	Спосіб корекції порушеhь обміhу кальцію у хворих hа сиhдром рейтера хламідійhої етіології
RU98120791A (ru)	2000-09-10	Способ диагностики, профилактики и коррекции неврологических и психических состоянии
UA29106A (uk)	2000-10-16	Спосіб лікування вібраційної хвороби
IT8621585V0 (it)	1986-04-18	Dispositivo per la guida in orizzontale della slitta, nei cestelli ed elementi in genere estraibili dei mobili.